Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alector ( (ALEC) ) has shared an announcement.
On May 7, 2026, Alector, Inc. entered into a sales agreement with TD Securities (USA) LLC, allowing the company to sell up to $125 million of common stock from time to time through at-the-market or negotiated offerings. The program, conducted under an effective shelf registration, gives Alector flexibility to control issuance parameters, is not obligatory to use, and can be terminated by either party on 10 days’ notice, with TD Cowen earning up to 3.0% of gross sales as compensation.
Proceeds from any share sales are earmarked for general corporate purposes, including funding research and development, manufacturing of product candidates, working capital, capital expenditures and potential future acquisitions or strategic transactions. The arrangement enhances Alector’s financing optionality and liquidity planning without immediately diluting shareholders, while formalizing customary indemnification and fee structures with TD Cowen as an ongoing financial services partner.
The most recent analyst rating on (ALEC) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Alector stock, see the ALEC Stock Forecast page.
Spark’s Take on ALEC Stock
According to Spark, TipRanks’ AI Analyst, ALEC is a Neutral.
Overall score is held back primarily by weak financial performance (persistent losses, significant recent revenue decline, and ongoing cash burn with a weaker 2025 balance sheet). Technicals are a relative strength with price above key moving averages and positive MACD. Valuation provides limited support due to negative earnings and no dividend yield provided.
To see Spark’s full report on ALEC stock, click here.
More about Alector
Alector, Inc. is a biotechnology company that develops therapeutic product candidates, focusing on research, development and manufacturing activities in the biopharmaceutical sector. The company deploys its capital toward advancing its pipeline, funding working capital needs, capital expenditures and broader corporate initiatives, as well as pursuing potential acquisitions or strategic transactions in complementary products, technologies or businesses.
Average Trading Volume: 724,004
Technical Sentiment Signal: Buy
Current Market Cap: $285.3M
See more insights into ALEC stock on TipRanks’ Stock Analysis page.